# WuXi Healthcare Ventures

> WuXi Healthcare Ventures is a VC fund backing Biotechnology and Health Care. See 38 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 38
- Last investment: Jul 2021
- Lead investor: 16%
- Fund size: $290M
- Last fund: Dec 2015
- Last updated: Aug 2026
- Website: http://www.wuxiventures.com

WuXi Healthcare Ventures is a VC fund in Cambridge focused on Biotechnology and Health Care. Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital.

## Contacts

5 contacts available for WuXi Healthcare Ventures. Shizune tracks 2 team members at WuXi Healthcare Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/wuxi-healthcare-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 23 | 61% |
| Health Care | 13 | 34% |
| Therapeutics | 10 | 26% |
| Pharmaceutical | 10 | 26% |
| Medical | 9 | 24% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 14 | 37% |
| Series A | 13 | 34% |
| Series C | 5 | 13% |
| Series D | 3 | 8% |
| Series E | 1 | 3% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 45% |
| China | 8 | 21% |
| Israel | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Edward Hu | Founding Partner | 5 | https://shizune.co/investors/profile/edward-hu |
| Sofie Qiao | Venture Partner | 0 | https://shizune.co/investors/profile/sofie-qiao |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $100M | Series D | Jul 13, 2021 |  |
| Zenas BioPharma | Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. |  | Series A | Mar 23, 2021 |  |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $50M | Series B | Jan 07, 2021 |  |
| XW Laboratories | XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders.Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve uponexisting medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform. | $40M | Series C | Sep 18, 2020 |  |
| Halda Therapeutics | Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $25M | Series A | Feb 01, 2019 |  |
| Antengene Corporation | Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.The company focuses on providing patients with innovative anti-tumor and anti-cancer therapies through new drug development, clinical research and drug production, enabling physicians to meet unmet medical needs in Asia. | $120M | Series B | Jan 02, 2019 |  |
| Refuge Biotechnologies | Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function. | $25M | Series B | May 02, 2018 |  |
| IDEAYA Biosciences | IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, locatedin South San Francisco and La Jolla, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery. | $94M | Series B | Mar 15, 2018 |  |
| Medeor Therapeutics | Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graftrejection better than currently available immunosuppression (anti-rejection) drugs. | $57M | Series B | Nov 27, 2017 |  |
| XW Laboratories | XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders.Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve uponexisting medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform. | $17.5M | Series B | Sep 20, 2017 |  |

10 of 38 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 6 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 6 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 5 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 4 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 3 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in China](https://shizune.co/investors/biotechnology-investors-china)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)
- [Biotech Investors in China](https://shizune.co/investors/biotech-investors-china)
- [Biotech VC Funds in China](https://shizune.co/investors/biotech-vc-funds-china)

## FAQ

### What does WuXi Healthcare Ventures invest in?

WuXi Healthcare Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact WuXi Healthcare Ventures?

Public channels for WuXi Healthcare Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at WuXi Healthcare Ventures?

The team at WuXi Healthcare Ventures includes Edward Hu (Founding Partner) and Sofie Qiao (Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co